Authors:
Alberio, L
Safa, O
Clemetson, KJ
Esmon, CT
Dale, GL
Citation: L. Alberio et al., Surface expression and functional characterization of alpha-granule factorV in human platelets: effects of ionophore A23187, thrombin, collagen, andconvulxin, BLOOD, 95(5), 2000, pp. 1694-1702
Authors:
Safa, O
Crippa, L
Della Valle, P
Sabbadini, MG
D'Angelo, SV
D'Angelo, A
Citation: O. Safa et al., IgG reactivity to phospholipid-bound beta(2)-glycoprotein I is the main determinant of the fraction of lupus anticoagulant activity quenched by addition of hexagonal (II) phase phospholipid in patients with the clinical suspicion of antiphospholipid-antibody syndrome, HAEMATOLOG, 84(9), 1999, pp. 829-838
Authors:
Della Valle, P
Crippa, L
Garlando, AM
Pattarini, E
Safa, O
D'Angelo, SV
D'Angelo, A
Citation: P. Della Valle et al., Interference of lupus anticoagulants in prothrombin time assays: implications for selection of adequate methods to optimize the management of thrombosis in antiphospholipid-antibody syndrome, HAEMATOLOG, 84(12), 1999, pp. 1065-1074
Authors:
Yegneswaran, S
Smirnov, MD
Safa, O
Esmon, NL
Esmon, CT
Johnson, AE
Citation: S. Yegneswaran et al., Relocating the active site of activated protein C eliminates the need for its protein S cofactor - A fluorescence resonance energy transfer study, J BIOL CHEM, 274(9), 1999, pp. 5462-5468
Authors:
Safa, O
Morrissey, JH
Esmon, CT
Esmon, NL
Citation: O. Safa et al., Factor VIIa/tissue factor generates a form of factor V with unchanged specific activity, resistance to activation by thrombin, and increased sensitivity to activated protein C, BIOCHEM, 38(6), 1999, pp. 1829-1837
Citation: O. Safa et al., Morphological changes and cytokine gene expression in tumor xenografts following treatment with the alkylphosphocholines hexadecylphosphocholine and perifosine, DRUGS TODAY, 34, 1998, pp. 15-26